SUPT7L

Across TCGA pan-cancer cohorts, SUPT7L mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SUPT7L’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where SUPT7L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SUPT7L is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

LSCC, PDAC, and LUAD are the cancer types where SUPT7L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUPT7L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	All	II,III,IV	+0.176	<.001	4	view →
PDAC	Male	All	−0.272	.022	2	view →
LUAD	All	All	−0.111	.013	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SUPT7L–LSCC

Open the LSCC breakdown →